Merck & Co., Inc. 13F Holdings · Q2 2026
Merck & Co., Inc. reported 13 securities worth $526.41M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: PSNL (35.75%), MRNA (30.71%), KYMR (16.82%). Among its top 25 positions this quarter: 3 new, 4 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PSNL | PERSONALIS INC | $188.2M | 35.75% | 14.0M | Hold |
| 2 | MRNA | MODERNA INC | $161.6M | 30.71% | 2.3M | Hold |
| 3 | KYMR | KYMERA THERAPEUTICS INC | $88.5M | 16.82% | 772,165 | Hold |
| 4 | AKTS | AKTIS ONCOLOGY INC | $30.7M | 5.83% | 952,844 | Hold |
| 5 | EIKN | EIKON THERAPEUTICS INC | $21.7M | 4.13% | 1.7M | Hold |
| 6 | TRDA | ENTRADA THERAPEUTICS INC | $12.8M | 2.43% | 1.7M | New |
| 7 | STRO | SUTRO BIOPHARMA INC | $9.0M | 1.72% | 272,351 | New |
| 8 | ALEC | ALECTOR INC | $7.1M | 1.35% | 3.5M | Hold |
| 9 | EVAX | EVAXION BIOTECH A/S | $3.8M | 0.71% | 1.2M | New |
| 10 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.7M | 0.33% | 93,414 | Hold |
| 11 | XLO | XILIO THERAPEUTICS INC | $1.0M | 0.19% | 105,982 | Hold |
| 12 | HURA | TUHURA BIOSCIENCES INC | $45,501 | 0.01% | 19,445 | Hold |
| 13 | NEUP | NEUPHORIA THERAPEUTICS INC | $43,818 | 0.01% | 10,027 | Hold |
| 14 | CARM | CARISMA THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
| 15 | EVAX | EVAXION BIOTECH A/S | $0 | 0.00% | 0 | Exited |
| 16 | STRO | SUTRO BIOPHARMA INC | $0 | 0.00% | 0 | Exited |
| 17 | TRDA | ENTRADA THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR